Oral Wegovy Approved in Europe and US: Weight Loss Pill Benefits, Lawsuits, and Aging Research Explained

# Wegovy Unpacked: Oral Pills, Lawsuits, Medicare Coverage & the Future of Weight Loss Medicine **Episode Description:** Wegovy is no longer just a weight loss injection—it's reshaping global healthcare, sparking lawsuits, and rewriting the rules of aging science. In this episode, we break down everything happening right now with semaglutide, Novo Nordisk's blockbuster drug, and what it means for patients, doctors, and the pharmaceutical industry. We cover the EU's landmark approval of **oral Wegovy**, the first GLP-1 pill approved for obesity, and reveal clinical trial data showing up to 17% average weight loss. Discover why oral Wegovy has already surpassed **3 million prescriptions** in the U.S. since its January launch—one of the fastest drug rollouts in history. But it's not all good news. We dig into the **mounting lawsuits** linking Wegovy to rare eye stroke (NAION) and severe gastroparesis, and what the multidistrict litigation means for patients and Novo Nordisk. We also explore surprising new research showing Wegovy may **slow biological aging** in HIV patients and deliver major benefits for adults over 65. Plus: Medicare's new $50/month Wegovy access program, the FDA crackdown on **compounded semaglutide** knockoffs, Novo Nordisk's legal battle with Eli Lilly, and Wegovy's potential expansion into liver disease treatment in South Korea. If you want to understand where obesity medicine, drug safety, and longevity science collide, this episode is essential listening. **Topics covered:** Wegovy oral tablet, semaglutide side effects, Wegovy lawsuit 2024, Medicare Wegovy coverage, GLP-1 drugs, compounded semaglutide FDA ban, Novo Nordisk vs Eli Lilly, Wegovy weight loss results, semaglutide and aging. Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai